Sign in

NCT07635641Recruiting

REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors

Source: ClinicalTrials.gov · Last updated 9 Jun 2026

Brief summary (registry, in English)

Some patients with head and neck cancer may develop a tumor recurrence in an area that has already been treated with radiotherapy. In these situations, surgery is not always possible, and giving radiotherapy again can be challenging because nearby healthy tissues and organs may already have received high radiation doses. The REPROton-HN study is evaluating the use of proton therapy for these patients. Proton therapy is a type of radiation treatment that can deliver radiation more precisely to the tumor while reducing exposure to surrounding healthy tissues. The aim of the study is to better understand how safe and effective proton therapy is when used as a second course of radiation treatment. Researchers will monitor side effects, tumor control, survival, and patients' quality of life. The results may help improve treatment planning and identify which patients are most likely to benefit from proton therapy in the future.

Status (registry)
Recruiting
Study type
Observational
Enrollment
50 (estimated)
First submitted
3 Jun 2026
Start date
29 May 2026
Primary completion date
30 Jun 2031
Lead sponsor
Istituto Clinico Humanitas
NCT number
NCT07635641

What you commit to

  • Study type: Observational
  • Planned participants: 50
  • From 29 May 2026 to the primary completion date, 30 Jun 2031
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • Age \< 18 years old

Other

  • ECOG\>3
  • Life expectancy \< 3 months
  • Inability to provide informed consent

Who the study is looking for

  • ≥ 18 years old
  • ECOG 0-2
  • Pathologically and or radiologically confirmed head and neck cancer recurrence
  • Indication for proton therapy
  • Written informed consent for REPRO-HN according to applicable legal and ethical requirements by the end of radiotherapy treatment

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
IRCCS Humanitas Research Hospital
Coordinator of this site? Confirm its status
RozzanoItalyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.